Skip to main content
. 2016 Jun 17;19(2):149–161. doi: 10.1007/s12094-016-1520-2

Fig. 6.

Fig. 6

Proposed treatment for patients with triple-negative metastatic cancer de novo or with a progression-free survival greater than 12 months